Gulf Pain Management Drugs Market

Gulf Pain Management Drugs Market Statistics 2020-2027:

The Gulf Pain Management Drugs Market size was valued at $851.08 million in 2019, and is projected to reach $1,047.91 million by 2027, registering a CAGR of 3.2%. 

Pain is an uncomfortable sensory and emotional sensation caused due to tissue injury or disease. It is caused due to injury and various diseases such as osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis, stomach ulcer, fibromyalgia and cancer. It can be defined as acute pain and chronic pain depending on duration.

This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak is anticipated to impact the growth of the pain management drugs market in the initial phase of the forecast period. The COVID-19 pandemic has stressed healthcare systems in the Gulf countries, so that pain services in many clinics are no longer open for public services because of safety. Furthermore, the demand for pain management drugs is expected to rise during the latter half of the forecast period owing to telemedicine which has become an appropriate and effective way to offer necessary medical services to patients with chronic pain. Through telemedicine, physicians are able to provide guidance to patients for physical exercises at-home for pain relief.

Chronic pain is mainly caused due to aging conditions of bone and joints and nerve damage and injury. Pain is managed by a particular set of drugs to reduce the symptoms or treat pain. Pain process is complex and there are various drugs that provide relief by acting through a variety of physiological mechanism. Opioids are the most prescribed pain medication. These are narcotic pain medications containing natural and synthetic opiates. Opioids are usually used for acute pain, such as short-term pain after surgery. Morphine, Fentanyl, Oxycodone and Codeine are some of the opioids used for pain management.

As per the statista, In the UAE, 4,500 new cancer cases are diagnosed each year, with cancers being the third leading cause of death after cardiovascular illnesses and injuries. This is expected to increase the need of cancer pain drugs for therapeutic purposes, thus fueling the gulf pain management drugs market growth. 

In recent times there is increased use of pain management drugs due to rise in aging population. Increasing prevalence of diseases such as cancer, diabetic neuropathy, osteoarthritis and chronic arthritis, increasing number of surgical procedures and increasing healthcare expenditure are some of the key factors driving the growth for the gulf pain management drugs market. In addition, increasing healthcare awareness is also fueling the growth of gulf pain management drugs market. However, increase in generic completion, patent expiration of blockbuster drugs and availability of substitutes such as pain relief devices are some of the major factors restraining the growth for gulf pain management drugs market. In addition, prescribing drug abuse would inhibit the growth of the market. 

Increasing R&D investment and outsourcing of pharmaceutical companies due to strong need for better treatment lead to market growth. In addition, novel molecule combination and drug delivery techniques would develop opportunity for the gulf pain management drugs market. However, side effects of pain management drugs could lead a challenge for the pain management drugs market.

Gulf Pain Management Drugs Market Segmentation

The gulf pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, it is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia, bone fracture, muscle sprain, acute appendicitis and other indications.  On the basis of pain type, it is segmented into chronic pain and acute pain. On the basis of country, it is divided into UAE, Saudi Arabia, Oman and rest of Gulf countries.

Gulf pain Management Drugs Market Segment review

On the basis of drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anti-migraine agents segment is anticipated to possess highest growth rate during the forecast period. 

By indication, the neuropathic pain segment accounted for a majority of the gulf pain management drugs market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain segment are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries and rise in prevalence of chronic diseases that lead to back pain.

The key players operating in the Gulf Pain Management Drugs Market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, Gulf Pharmaceutical Industries (Julphar), Oman pharmaceutical products co. Llc and GlaxoSmithKline Plc.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the gulf pain management drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
• Quantitative analysis from 2019 to 2027 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
• The gulf pain management drugs market size and estimations are based on a comprehensive analysis of key developments in the industry.
• Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

 Gulf Pain Management Drugs Market Report Highlights